Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén & Peter Ellmark. (2021) Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy 21:12, pages 1635-1646.
Read now
Read now
Articles from other publishers (22)
José Javier Morales-Núñez, José Francisco Muñoz-Valle, Mariel García-Chagollán, Sergio Cerpa-Cruz, Gloria Esther Martínez-Bonilla, Vianey Monserrat Medina-Rosales, Saúl Alberto Díaz-Pérez, Ferdinando Nicoletti & Jorge Hernández-Bello. (2023) Aberrant B-cell activation and B-cell subpopulations in rheumatoid arthritis: analysis by clinical activity, autoantibody seropositivity, and treatment. Clinical and Experimental Immunology.
Crossref
Crossref
Cheri Peyton Goodall, Benjamin Schwarz, Ekaterina Selivanovitch, John Avera, Joseph Wang, Heini Miettinen & Trevor Douglas. (2021) Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling. ACS Applied Bio Materials 4:12, pages 8205-8214.
Crossref
Crossref
Diana Stoycheva, Hasan Simsek, Willi Weber, Anja E. Hauser & Enrico Klotzsch. (2021) External cues to drive B cell function towards immunotherapy. Acta Biomaterialia 133, pages 222-230.
Crossref
Crossref
Benjamin Shibru, Katharina Fey, Stephan Fricke, André-René Blaudszun, Friederike Fürst, Max Weise, Sabine Seiffert, Maria Katharina Weyh, Ulrike Köhl, Ulrich Sack & Andreas Boldt. (2021) Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry. Frontiers in Immunology 12.
Crossref
Crossref
Raquel Delgado, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater & Eric Eldering. (2021) Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers 13:12, pages 3084.
Crossref
Crossref
Robby Divine, Ha V. Dang, George Ueda, Jorge A. Fallas, Ivan Vulovic, William Sheffler, Shally Saini, Yan Ting ZhaoInfencia Xavier Raj, Peter A. Morawski, Madeleine F. Jennewein, Leah J. Homad, Yu-Hsin Wan, Marti R. TooleyFranziska SeegerAli EtemadiMitchell L. Fahning, James Lazarovits, Alex Roederer, Alexandra C. Walls, Lance Stewart, Mohammadali Mazloomi, Neil P. King, Daniel J. Campbell, Andrew T. McGuire, Leonidas Stamatatos, Hannele Ruohola-Baker, Julie Mathieu, David Veesler & David Baker. (2021) Designed proteins assemble antibodies into modular nanocages. Science 372:6537.
Crossref
Crossref
Peter D. Koch, Mikael J. Pittet & Ralph Weissleder. (2020)
The chemical biology of IL-12 production
via
the non-canonical NFkB pathway
. RSC Chemical Biology 1:4, pages 166-176.
Crossref
Crossref
Frank Mickoleit, Valérie Jérôme, Ruth Freitag & Dirk Schüler. (2020) Bacterial Magnetosomes as Novel Platform for the Presentation of Immunostimulatory, Membrane‐Bound Ligands in Cellular Biotechnology. Advanced Biosystems 4:3, pages 1900231.
Crossref
Crossref
Suresh de Silva, George Fromm, Casey W. Shuptrine, Kellsey Johannes, Arpita Patel, Kyung Jin Yoo, Kaiwen Huang & Taylor H. Schreiber. (2020) CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. Cancer Immunology Research 8:2, pages 230-245.
Crossref
Crossref
Jialing Zhang, Stephan S. Späth, Sherman M. Weissman & Samuel G. Katz. 2020. Cell Reprogramming for Immunotherapy. Cell Reprogramming for Immunotherapy
139
171
.
Valérie Jérôme, Ruth Freitag, Dirk Schüler & Frank Mickoleit. (2019) SEAP activity measurement in reporter cell-based assays using BCIP / NBT as substrate. Analytical Biochemistry 585, pages 113402.
Crossref
Crossref
Fei Fei Guo & Jiu Wei Cui. (2019) The Role of Tumor-Infiltrating B Cells in Tumor Immunity. Journal of Oncology 2019, pages 1-9.
Crossref
Crossref
Kerstin Wennhold, Alexander Shimabukuro-Vornhagen & Michael von Bergwelt-Baildon. (2019) B Cell-Based Cancer Immunotherapy. Transfusion Medicine and Hemotherapy 46:1, pages 36-46.
Crossref
Crossref
James M. Mathew, Jessica H. Voss, Scott T. McEwen, Iwona Konieczna, Arjun Chakraborty, Xuemei Huang, Jie He, Lorenzo Gallon, Richard S. Kornbluth & Joseph R. Leventhal. (2018) Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance. Scientific Reports 8:1.
Crossref
Crossref
Manzoor M KhanManzoor M. Khan. 2016. Immunopharmacology. Immunopharmacology
397
425
.
Amer Assal, Justin Kaner, Gopichand Pendurti & Xingxing Zang. (2015) Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 7:11, pages 1169-1186.
Crossref
Crossref
Ingegerd Elvers, Jason Turner-Maier, Ross Swofford, Michele Koltookian, Jeremy Johnson, Chip Stewart, Cheng-Zhong Zhang, Steven E. Schumacher, Rameen Beroukhim, Mara Rosenberg, Rachael Thomas, Evan Mauceli, Gad Getz, Federica Di Palma, Jaime F. Modiano, Matthew Breen, Kerstin Lindblad-Toh & Jessica Alföldi. (2015) Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Research 25:11, pages 1634-1645.
Crossref
Crossref
Karīna Siliņa, Undīne Rulle, Zane Kalniņa & Aija Linē. (2014) Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?. Cancer Immunology, Immunotherapy 63:7, pages 643-662.
Crossref
Crossref
Sachin Gupta, James M. Termini, Francesca N. Raffa, Cindi-Ann Williams, Richard S. Kornbluth & Geoffrey W. Stone. (2014)
Vaccination with a Fusion Protein That Introduces HIV-1 Gag Antigen into a Multitrimer CD40L Construct Results in Enhanced CD8
+
T Cell Responses and Protection from Viral Challenge by Vaccinia-Gag
. Journal of Virology 88:3, pages 1492-1501.
Crossref
Crossref
Lee P. Richman & Robert H. Vonderheide. (2014) Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer. Cancer Immunology Research 2:1, pages 19-26.
Crossref
Crossref
Edwin Bremer. (2013) Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. ISRN Oncology 2013, pages 1-25.
Crossref
Crossref
Ann L. White, H. T. Claude Chan, Ruth R. French, Stephen A. Beers, Mark S. Cragg, Peter W. M. Johnson & Martin J. Glennie. (2013) Fc?R??B controls the potency of agonistic anti-TNFR mAbs. Cancer Immunology, Immunotherapy 62:5, pages 941-948.
Crossref
Crossref